企業プロフィール
Enliven Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- ELVN
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
59.82 USD (+1.53%)
終値
最終更新: 2026年8月21日
2.16B USD
時価総額
株価変動の要因
As of Aug 21, 2026, ELVN closed up 1.53% at $59.82. No new same-company headline was identified in the current news window.
企業概要
Precision Oncology
Enliven Therapeutics develops small-molecule precision medicines intended to improve both survival and quality of life for people with cancer.
ELVN-001
ELVN-001 is a selective BCR::ABL1 tyrosine-kinase inhibitor for chronic myeloid leukemia. It is designed to retain antileukemic activity while reducing off-target effects associated with existing therapies.
Late-Stage Development Path
Clinical development is moving from Phase 1 evaluation toward the pivotal ENABLE-2 program, positioning ELVN-001 as the company's principal potential registrational asset.
今後のカタリスト
- Phase 1 data update for ELVN-001 around mid-2026.
- Initiation of the Phase 3 ENABLE-2 trial in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。